checkAd

     125  0 Kommentare Takeda Provides Update on TAK-994 Clinical Program - Seite 3

    Medical information

    This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.


    Business Wire (engl.)
    0 Follower
    Autor folgen

    Weitere Artikel des Autors

    Seite 3 von 3

    Takeda Provides Update on TAK-994 Clinical Program - Seite 3 Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that a safety signal has emerged in Phase 2 studies of TAK-994, an investigational oral orexin agonist. As an immediate precautionary measure, the company has …

    Schreibe Deinen Kommentar

    Disclaimer